with moderate to severe CKD, received at least one OAD prescription that was
(32.6 vs. 13.7%, p<0.05) compared to NKF non-concordant group.

Intralesional MMF could be adopted as a
safety and effective adjunctive line of treatment especially in localized plaque
psoriasis patients, response to different concentrations (3.125, 6.25, 12.5
and 25 mg/ml) of MMF have been objectively evaluated and compared to control
5x10^6 cells/ml). The study was designed to evaluate the effect of the
and comparison between groups was performed using the Student’s t
costs and patient-related outcomes. No significant difference was observed in the
ANOVA, P>0.05). The difference between baseline and visits 4 and 8 was

- **PSS1**
  - **OBJECTIVES:** Therapeutic trial of intralesional injection of mycophenolate
    - **METHODS:** In hundred
    - **RESULTS:** The mean concentration of mycophenolic acid was significantly
      - **CONCLUSIONS:** Maximum response to MMF was achieved 8 weeks after initiation of therapy.

- **PSS2**
  - **OBJECTIVES:** Comparing treatment patterns and efficacy of ranibizumab for
    - **RESULTS:** No significant difference could be observed in the efficacy of different concentrations with different regimens. No systemic or local adverse effects were noted apart from mild and transient burning sensation especially with higher concentrations.

- **SNS1**
  - **OBJECTIVES:** Evaluation of the relationship between self-monitoring of blood glucose (SMBG) test strip utilization and medication intensification in Type 2 diabetes mellitus.
  - **METHODS:** A retrospective study of Marketscan data examined patients with T2DM with ≥2 prescription claims or a 90-day supply of at least one non-insulin antihyperglycemic (AH) agent during a 4-month baseline period between July 1, 2006 to December 31, 2009. The first claim for an AH was considered the “index treatment” and was required. Patient adherence to the HbA1C testing guideline was defined as an

  - **RESULTS:** Of the 14,164 patients who met the study criteria, 4,419(31.20%) met
  - **CONCLUSIONS:** Adherence to ADA guidelines on Hba1c testing frequency and therapy modification correlated with improved outcomes one year after initial drug treatment.